TD Waterhouse Canada Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,119 shares of the medical research company's stock after purchasing an additional 661 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in Thermo Fisher Scientific were worth $18,267,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Teachers Retirement System of The State of Kentucky raised its stake in shares of Thermo Fisher Scientific by 2.0% in the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 66,746 shares of the medical research company's stock valued at $34,723,000 after purchasing an additional 1,321 shares during the period. Tower Research Capital LLC TRC lifted its stake in Thermo Fisher Scientific by 72.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 21,330 shares of the medical research company's stock valued at $11,097,000 after acquiring an additional 8,946 shares in the last quarter. Tradition Wealth Management LLC boosted its position in Thermo Fisher Scientific by 6.5% during the 4th quarter. Tradition Wealth Management LLC now owns 1,201 shares of the medical research company's stock worth $625,000 after acquiring an additional 73 shares during the last quarter. Transce3nd LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $64,000. Finally, Kelly Lawrence W & Associates Inc. CA grew its holdings in shares of Thermo Fisher Scientific by 51.5% in the 4th quarter. Kelly Lawrence W & Associates Inc. CA now owns 500 shares of the medical research company's stock valued at $260,000 after acquiring an additional 170 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts have issued reports on TMO shares. UBS Group dropped their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday. Scotiabank raised their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research note on Monday, February 3rd. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Evercore ISI cut their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $618.68.
Get Our Latest Research Report on Thermo Fisher Scientific
Insiders Place Their Bets
In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Price Performance
TMO stock traded down $5.07 during midday trading on Thursday, reaching $426.57. The company had a trading volume of 3,661,206 shares, compared to its average volume of 1,736,253. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The company has a market capitalization of $161.03 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The stock has a 50 day moving average price of $489.25 and a 200-day moving average price of $528.84.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
